-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Stroke survivors have an increased risk of depression and fractures
.
Observational studies indicate that selective serotonin reuptake inhibitors (SSRIs) are associated with increased fracture risk
Stroke
Recently, the heart blood vessels published on the prestigious journal Stroke disease area research article, the researchers sought to determine stroke survivors and fracture risk associated with the use of SSRIs and falls,The risk of epilepsy and recurrent stroke
.
According to the protocol registered in PROSPERO (CRD42020192632), the researchers conducted a systematic review and meta-analysis of RCTs for assessing the effects of SSRIs among stroke survivors
.
Researchers searched WebofScience, EMBASE, PsycINFO and OvidMedline/PubMed databases, clinical trial grade centers, and grey literature to determine RCTs that compared SSRIs with placebo or no intervention and reported fracture risk in adult survivors of hemorrhagic or ischemic stroke.
The researchers retrieved a total of 683 records, including 4 RCTs with a duration of 6 months.
A total of 6549 participants were included in the meta-analysis: 3 studies of fluoxetine and 1 study of citalopram
According to the existing RCTs of fluoxetine and citalopram, the use of SSRI for 6 months doubled the risk of fracture in stroke survivors
Original source:
Joshua S.
Jones.
et al.
Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor A Systematic Review and Meta-Analysis .
stroke.
2021.
Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor A Systematic Review and Meta-Analysis In this message